John C. Byrd

John Byrd is the pioneering investigator who led development of ibrutinib for CLL and other B-cell malignancies, including the landmark RESONATE trials establishing ibrutinib's efficacy in previously treated and del17p/TP53-mutated CLL. His laboratory characterized BTK as an essential survival kinase in CLL B cells, providing the rationale for targeted BTK inhibition. His translational and clinical work has produced multiple FDA approvals and fundamentally transformed CLL treatment by replacing chemotherapy with targeted therapies. He is among the most impactful hematology investigators of his generation.